Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders
Open accessAbstract
OBJECTIVE: To explore possible benefits of a nicotinic acetylcholine receptor (nAChR) agent for autistic symptoms based on postmortem observation of nAChR abnormalities (deficient α4β2 nAChRs, excess α7 nAChRs) in brains of patients with autism. METHOD: Mecamylamine, because of its safety record in children with other disorders, was chosen for this first exploration. Twenty children with autism spectrum disorder age 4-12 years were randomly assigned for 14 weeks to placebo (n=8) or mecamylamine (n=12) in ascending fixed doses: 0.5 mg/day for 6 weeks, 2.5 mg for 2 weeks, then 5 mg/day for 6 weeks. Improvement was rated by a blinded independent evaluator. Because of small sample, data analysis was descriptive. RESULTS: Eighteen participants (10 mecamylamine, 8 placebo) completed the study. All doses were well tolerated; the only side effect of note was constipation (50% compared with 25% of placebo group). Three children had clinically nonsignificant electrocardiographic QT prolongation. Both groups showed modest to moderate improvement, but differences between groups were negligible. On the primary outcome measure, the Ohio Autism Clinical Impressions Scale, 90% of the active treatment group showed improvement at some point (but only 40% sustained it), compared with 62% on placebo. Of the four in active treatment that sustained improvement, three had a maximum dose of 0.13-0.15 mg/kg/day, while those who regressed had doses ≥0.18 mg/kg/day. Graphed means suggested better outcome with lower mg/kg and longer medication duration. Four parents spontaneously reported reduced hyperactivity and irritability and better verbalization and continued mecamylamine at their own expense. CONCLUSION: Mecamylamine appeared to be safe, but not very effective in autism. The suggestion of better results at lower doses and longer exposure warrants consideration for future trials. The next step would be exploration of a more specific α4β2 nAChR agonist, such as varenicline.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Evidence supporting a significant but complex role of nicotine and nicotinic receptors in ARBS can be gleaned from clinical studies with different primary outcomes that also report on these data, as well as well-conducted case series.
“evidence supporting a significant but complex role of nicotine and nicotinic receptors in these syndromes can be gleaned from a variety of clinical studies with different primary outcomes that also report on these data (Arnold et al., 2012; Conners et al., 1996; Drusch et al., 2013; Newhouse et al., 1994), as well as well-conducted case series (Mayer et al., 2001; Rosin et al., 2001)”
From Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states (2015) · cites this paper as Arnold et al., 2012
The reports of decreased irritability in those cases were spontaneously reported by parents, and treatment was continued in these cases.
“This was spontaneously reported by parents, and was sufficiently convincing that treatment was continued in these cases.”
From Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states (2015) · cites this paper as Arnold et al., 2012
In a small trial of mecamylamine in autism, there was no clinically or statistically significant benefit.
“This small study reported no clinically or statistically significant benefit”
From Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states (2015) · cites this paper as Arnold et al., 2012
In that trial, there was anecdotal evidence of decreased irritability in four cases.
“but provided anecdotal evidence of decreased irritability in four cases.”
From Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states (2015) · cites this paper as Arnold et al., 2012
Cites
Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., Metzger, L. M., Shoushtari, C. S., Splinter, R., & Reich, W. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025014929212 · Cited by 1,611 · see citing works
Postmortem brain abnormalities of the glutamate neurotransmitter system in autism
Purcell, A. E., Jeon, O. H., Zimmerman, A. W., Blue, M. E., & Pevsner, J. (2001) · Neurology · doi:10.1212/wnl.57.9.1618 · Cited by 518 · see citing works
Fatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C., & Realmuto, G. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01430-0 · Cited by 500 · see citing works
Effect of nicotine and nicotinic receptors on anxiety and depression
Picciotto, M. R., Brunzell, D. H., & Caldarone, B. J. (2002) · Neuroreport · doi:10.1097/00001756-200207020-00006 · Cited by 483 · see citing works
Effect of smoking history on [3H]nicotine binding in human postmortem brain
Breese, C. R., Marks, M. J., Logel, J., Adams, C. E., Sullivan, B., Collins, A. C., & Leonard, S. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36798-9 · Cited by 396 · see citing works
Cholinergic Activity in Autism: Abnormalities in the Cerebral Cortex and Basal Forebrain
Perry, E. K., Lee, M., Martin-Ruiz, C. M., COURT, J. A., Volsen, S. G., Merrit, J., Folly, E. A., Iversen, P. E., Bauman, M. L., Perry, R. H., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1058 · Cited by 390 · see citing works
Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies
Perry, D. C., Dávila-Garcı́a, M. I., Stockmeier, C. A., & Kellar, K. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38304-1 · Cited by 362 · see citing works
Effects of scopolamine and nicotine on human rapid information processing performance
Wesnes, K. A., & Warburton, D. M. (1984) · Psychopharmacology · doi:10.1007/bf00427761 · Cited by 354 · see citing works
Nicotinic receptor subtypes and cognitive function
Levin, E. D. (2002) · Journal of Neurobiology · doi:10.1002/neu.10151 · Cited by 354 · see citing works
Transdermal nicotine effects on attention
Levin, E. D., Conners, C. K., Silva, D., Hinton, S. C., Meck, W. H., March, J. S., & Rose, J. E. (1998) · Psychopharmacology · doi:10.1007/s002130050750 · Cited by 331 · see citing works
Blatt, G. J., Fitzgerald, C. M., Guptill, J. T., Booker, A. B., Kemper, T. L., & Bauman, M. L. (2001) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1013238809666 · Cited by 322 · see citing works
Neurochemical correlates of autistic disorder: a review of the literature
Lam, K. S. L., Aman, M. G., & Arnold, L. E. (2006) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2005.03.003 · Cited by 318 · see citing works
Self-citationSmoking, nicotine and human performance
Wesnes, K. A., & Warburton, D. M. (1983) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(83)90072-4 · Cited by 243 · see citing works
Alkondon, M., & Albuquerque, E. X. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.86.6.3043 · Cited by 240 · see citing works
Nicotinic receptor abnormalities in the cerebellar cortex in autism
Lee, M. (2002) · Brain · doi:10.1093/brain/awf160 · Cited by 232 · see citing works
Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD).
Conners, C. K., Levin, E. D., Sparrow, E. P., Hinton, S. C., Erhardt, D., Meck, W. H., Rose, J. E., & March, J. S. (1996) · PubMed · Cited by 218 · see citing works
ARNOLD, L. E., VITIELLO, B., MCDOUGLE, C., SCAHILL, L., SHAH, B., GONZALEZ, N. M., CHUANG, S., DAVIES, M., HOLLWAY, J., AMAN, M. G., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00011 · Cited by 218 · see citing works
Sparks, J. A., & Pauly, J. R. (1999) · Psychopharmacology · doi:10.1007/s002130050818 · Cited by 188 · see citing works
Effects of Nicotine on Stimulus Sensitivity and Response Bias in a Visual Vigilance Task
Wesnes, K. A., Warburton, D. M., & Matz, B. (2008) · Neuropsychobiology · doi:10.1159/000117935 · Cited by 172 · see citing works
Molecular analysis of nicotinic receptor expression in autism
Martin-Ruiz, C. M., Lee, M., Perry, R. H., Baumann, M., Court, J. A., & Perry, E. K. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.01.003 · Cited by 141 · see citing works
Aman, M. G., Buican, B., & Arnold, L. E. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603321666171 · Cited by 139 · see citing works
Court, J. A., Lloyd, S., Thomas, N., Piggott, M. A., Marshall, E. F., Morris, C. M., Lamb, H., Perry, R. H., Johnson, M., & Perry, E. K. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00088-8 · Cited by 135 · see citing works
Effect of cocaine self-administration on dopamine D2 receptors in rhesus monkeys
Moore, R. J., Vinsant, S. L., Nader, M. A., Porrino, L. J., & Friedman, D. P. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199809)30:1 · Cited by 134 · see citing works
Hardan, A. Y., & Handen, B. L. (2002) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454602760386923 · Cited by 130 · see citing works
Effects of nicotine and mecamylamine on rat dorsal raphe neurons
Mihailescu, S., Palomero-Rivero, M., Meade-Huerta, P., Maza-Flores, A., & Drucker-Colı́n, R. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00658-x · Cited by 117 · see citing works
Transdermal Nicotine and Haloperidol in Tourette's Disorder: A Double-Blind Placebo-Controlled Study
Silver, A. A., Shytle, D., Philipp, M. K., Wilkinson, B. J., McConville, B., & Sanberg, P. R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0908 · Cited by 111 · see citing works
Silver, A. A., Shytle, R. D., Sheehan, K. H., Sheehan, D. V., RAMOS, A., & Sanberg, P. R. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200109000-00020 · Cited by 102 · see citing works
Deutsch, S. I., Urbano, M. R., Neumann, S. A., Burket, J. A., & Katz, E. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181d6f7ad · Cited by 99 · see citing works
Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Aman, M. G., Hollway, J. A., McDougle, C. J., Scahill, L., Tierney, E., McCracken, J. T., Arnold, L. E., Vitiello, B., Ritz, L., Gavaletz, A., et al. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0133 · Cited by 80 · see citing works
Self-citationMecamylamine (Inversine®): an old antihypertensive with new research directions
Shytle, R. D., Penny, E., Silver, A. A., Goldman, J., & Sanberg, P. R. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001416 · Cited by 76 · see citing works
Kassiou, M., Eberl, S., Meikle, S. R., Birrell, A., Constable, C., Fulham, M. J., Wong, D. F., & Musachio, J. L. (2001) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00206-7 · Cited by 58 · see citing works
Handen, B. L., Johnson, C. R., McAuliffe-Bellin, S., Murray, P. J., & Hardan, A. Y. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0024 · Cited by 58 · see citing works
Nicotinic acetylcholine receptor knockout mice as animal models for studying receptor function
Marubio, L. M., & Changeux, J. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00007-8 · Cited by 55 · see citing works
Nicotinic receptors and hippocampal synaptic plasticity…it’s all in the timing
McGehee, D. S. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02127-5 · Cited by 53 · see citing works
Nicotinic Receptors in the Nervous System
Levin, E. D. (2001) · CRC Press eBooks · doi:10.1201/9781420038521 · Cited by 51 · see citing works
Giniatullin, R. A., Sokolova, E., Angelantonio, S. D., Skorinkin, A., Talantova, M. V., & Nistri, A. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.4.778 · Cited by 46 · see citing works
Nicotinic cholinergic antagonists: A novel approach for the treatment of autism
Lippiello, P. M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.11.015 · Cited by 43 · see citing works
Incidental learning, distraction, and sustained attention in hyperactive and control subjects
Aman, M. G., & Turbott, S. H. (1986) · Research on Child and Adolescent Psychopathology · doi:10.1007/bf00915437 · Cited by 41 · see citing works
Effects of transdermal nicotine on cognitive performance in Down's syndrome
Seidl, R., Tiefenthaler, M., Hauser, E., & Lübec, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02848-8 · Cited by 24 · see citing works
Smoking, Nicotine and Human Performance
Wesnes, K. A., & Parrott, A. C. (1992) · Elsevier eBooks · doi:10.1016/b978-0-12-650352-4.50011-2 · Cited by 18 · see citing works
Anand, R., Stephanie, A., Ponath, G. D., Jordan, I., Nasir, M. I., & Susan, B. (2011) · InTech eBooks · doi:10.5772/20752 · Cited by 11 · see citing works
Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome
Bernert, G., Šustrová, M., Sovcikova, E., Seidl, R., & Lübec, G. (2001) · Springer eBooks · doi:10.1007/978-3-7091-6262-0_19 · Cited by 10 · see citing works
Nicotine and Cognition in Young and Aged Nonhuman Primates
Buccafusco, J. J., & Terry, A. V. (2001) · Frontiers in neuroscience · doi:10.1201/9781420038521.ch8 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Nicotinic ACh receptors as therapeutic targets in CNS disorders
Dineley, K. T., Pandya, A. A., & Yakel, J. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.002 · Cited by 449 · see citing works
Fung, L. K., Mahajan, R., Nozzolillo, A., Bernal, P., Krasner, A., Jo, B., Coury, D., Whitaker, A., Veenstra-Vanderweele, J., & Hardan, A. Y. (2016) · Pediatrics · doi:10.1542/peds.2015-2851k · Cited by 294 · see citing works
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L., Long, S., Ke, X., Fukunaga, K., Lu, Y., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 272 · see citing works
Frye, R. E., Slattery, J. M., Delhey, L. M., Furgerson, B. N., Strickland, T., Tippett, M., Sailey, A., Wynne, R. A., Rose, S., Melnyk, S., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.168 · Cited by 220 · see citing works
Treatment of Autism Spectrum Disorder in Children and Adolescents
DeFilippis, M., & Wagner, K. D. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4346 · Cited by 178 · see citing works
Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics
Kazdoba, T. M., Leach, P. T., Yang, M., Silverman, J. L., Solomon, M., & Crawley, J. N. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5003 · Cited by 172 · see citing works
Picciotto, M. R., Lewis, A. S., van Schalkwyk, G. I., & Mineur, Y. S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.028 · Cited by 157 · see citing works
Outcome Measures for Clinical Trials in Down Syndrome
Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., d'Ardhuy, X. L., Capone, G., Conners, F. A., Mervis, C. B., Abbeduto, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.247 · Cited by 153 · see citing works
Zhou, M. S., Nasir, M., Farhat, L. C., Kook, M., Artukoglu, B. B., & Bloch, M. H. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.03.007 · Cited by 129 · see citing works
Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research
Farmer, C., Thurm, A. E., & Grant, P. (2013) · Drugs · doi:10.1007/s40265-013-0021-7 · Cited by 117 · see citing works
de Pablo, G. S., Jordá, C. P., Vaquerizo‐Serrano, J., Moreno, C., Cabras, A., Arango, C., Hernandez, P. A., Veenstra-VanderWeele, J. M., Simonoff, E. A., Fusar‐Poli, P., et al. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.03.033 · Cited by 92 · see citing works
Approaches to studying and manipulating the enteric microbiome to improve autism symptoms
Frye, R. E., Slattery, J. M., MacFabe, D. F., Allen‐Vercoe, E., Parker, W., Rodakis, J., Adams, J. B., Krajmalnik‐Brown, R., Bolte, E. R., Kahler, S. G., et al. (2015) · Microbial Ecology in Health and Disease · doi:10.3402/mehd.v26.26878 · Cited by 75 · see citing works
Wang, L., Almeida, L. E. F., Spornick, N., Kenyon, N. J., Kamimura, S., Khaibullina, A., Nouraie, M. S., & Quezado, Z. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4058-z · Cited by 71 · see citing works
Uzunova, G., Hollander, E., & Shepherd, J. D. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660046 · Cited by 70 · see citing works
Potential therapeutic uses of mecamylamine and its stereoisomers
Nickell, J. R., Grinevich, V. P., Siripurapu, K. B., Smith, A. M., & Dwoskin, L. P. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.04.005 · Cited by 52 · see citing works
Iffland, M., Livingstone, N., Jorgensen, M. L., Hazell, P., & Gillies, D. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011769.pub2 · Cited by 55 · see citing works
The Arizona Cognitive Test Battery for Down Syndrome: Test-Retest Reliability and Practice Effects
Edgin, J. O., Anand, P., Rosser, T. C., Pierpont, E. I., Figueroa, C., Hamilton, D., Huddleston, L. B., Mason, G. M., Spanò, G., Toole, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.215 · Cited by 39 · see citing works
Bertelli, M. O., Azeem, M. W., Underwood, L., Scattoni, M. L., Persico, A. M., Ricciardello, A., Sappok, T., Bergmann, T. J., Keller, R., Bianco, A., et al. (2022) · Springer eBooks · doi:10.1007/978-3-319-95720-3_16 · Cited by 41 · see citing works
D, A. O. M., Blakeley‐Smith, A., Johnson, L. L., Kem, W. R., & Freedman, R. (2016) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-016-2890-6 · Cited by 34 · see citing works
Lewis, A. S., van Schalkwyk, G. I., Lopez, M. O., Volkmar, F. R., Picciotto, M. R., & Sukhodolsky, D. G. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3536-7 · Cited by 29 · see citing works
van Schalkwyk, G. I., Lewis, A. S., Qayyum, Z., Koslosky, K., Picciotto, M. R., & Volkmar, F. R. (2015) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-015-2471-0 · Cited by 28 · see citing works
Koevoet, D., Deschamps, P. K. H., & Kenemans, J. L. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1078586 · Cited by 28 · see citing works
Lewis, A. S., & Picciotto, M. R. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107929 · Cited by 23 · see citing works
Update on psychopharmacology for autism spectrum disorders
Bertelli, M. O., Rossi, M., Keller, R., & Lassi, S. (2016) · Advances in Mental Health and Intellectual Disabilities · doi:10.1108/amhid-10-2015-0049 · Cited by 18 · see citing works
Acetylcholinesterase inhibitors for autistic spectrum disorders
Ure, A. M., Cox, G., Haslam, R., & Williams, K. J. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013851.pub2 · Cited by 17 · see citing works
Mahmood, H. M., Aldhalaan, H., Alshammari, T. K., Alqasem, M., Alshammari, M. A., Albekairi, N. A., & AlSharari, S. D. (2020) · Autism Research · doi:10.1002/aur.2342 · Cited by 17 · see citing works
Autism in context 2: Assessment, intervention and services in A ustralia
Williams, K. J., Woolfenden, S. R., Roberts, J., Rodger, S., Bartak, L., & Prior, M. R. (2014) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12456 · Cited by 14 · see citing works
Designing Selective Modulators for the Nicotinic Receptor Subtypes: Challenges and Opportunities
Manetti, D., Bellucci, C., Chiaramonte, N., Dei, S., Teodori, E., & Romanelli, M. N. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0169 · Cited by 12 · see citing works
Persico, A. M., Asta, L., Chehbani, F., Mirabelli, S., Parlatini, V., Cortese, S., Arango, C., & Vitiello, B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111176 · Cited by 10 · see citing works
Norleans, J., Wang, J., Kuryatov, A., Leffler, A. E., Doebelin, C., Kamenecka, T. M., & Lindstrom, J. M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006253 · Cited by 10 · see citing works
Assessing Change in Core Autism Symptoms: Challenges for Pharmacological Studies
Aman, M. G., Arnold, L. E., & Hollway, J. A. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.28999.mga · Cited by 9 · see citing works
Buck, J. M., O’Neill, H. C., & Stitzel, J. A. (2021) · Behavior Genetics · doi:10.1007/s10519-021-10071-x · Cited by 7 · see citing works
Nicotinic acetylcholine receptors-targeting drug discovery
Zhang, D., Zheng, H., Cui, K., Li, Y., Liu, C., Mao, J., Zheng, J., & Wan, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118679 · Cited by 5 · see citing works
Anti-Anxiety Medications and Novel Treatments for Autism
Deb, S. S., Roy, M., Limbu, B., & Bertelli, M. O. (2022) · Autism and child psychopathology series · doi:10.1007/978-3-030-88538-0_51 · Cited by 5 · see citing works
Gould, K., Martin, R. J., Bottini, S. B., Crowley-Zalaket, J., Losh, A., McCammon, M. N., Wolgemuth, J. R., & Anderson, C. M. (2023) · Journal of Positive Behavior Interventions · doi:10.1177/10983007231200541 · Cited by 5 · see citing works
From bedside to bench and back: Translating ASD models
Drozd, H. P., Karathanasis, S. F., Molosh, A. I., Lukkes, J. L., Clapp, D. W., & Shekhar, A. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.10.003 · Cited by 3 · see citing works
Effective Medications for Treating Individuals with Autism Spectrum Disorder
Farmer, C., Leon, J., & Hommer, R. E. (2019) · Pediatric school psychology · doi:10.1007/978-3-030-15541-4_6 · Cited by 2 · see citing works
Stein, M. A., & King, B. H. (2016) · The American Journal of Bioethics · doi:10.1080/15265161.2016.1145298 · Cited by 2 · see citing works
Mukaetova‐Ladinska, E. B., & Perry, E. K. (2015) · Contemporary clinical neuroscience · doi:10.1007/978-1-4939-2190-4_15 · Cited by 1 · see citing works
Ging-Jehli, N. R., Manda, D., Hollway, J. A., Hurt, E. A., Moone, S., & Arnold, L. E. (2020) · Journal of Developmental and Physical Disabilities · doi:10.1007/s10882-020-09776-4
Siniscalco, D., & Antonucci, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-16321-5_11
- Authors
- Arnold, L. E., Aman, M. G., Hollway, J., Hurt, E., Bates, B., Li, X., Farmer, C., Anand, R., Thompson, S., Ramadan, Y., & Williams, C.
- Affiliations
- The Ohio State University (US)
- The Ohio State University
- Corresponding author
- Arnold, L. Eugene
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-06
- Volume
- 22
- Issue
- 3
- Pages
- 198-205
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- PMC
- PMC3417385
- OpenAlex
- W2092192222
- Cited by
- 42
- References
- 43
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 9 · 2014: 2 · 2013: 2
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Child and Adolescent Psychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Autism Speaks (AS2368)
- Ohio State University (UL1RR025755)
- Johns Hopkins University
- National Institutes of Health (UL1TR000090)
- Center for Clinical and Translational Research
- National Center for Research Resources (UL1RR025755)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- mecamylamine, autism spectrum disorder, nicotinic acetylcholine receptors, alpha4beta2 nAChR, alpha7 nAChR, children, drug safety, constipation, QT prolongation, dose-response relationship, varenicline, hyperactivity, irritability
- MeSH terms
- Child, Child Development Disorders, Pervasive, Child, Preschool, Constipation, Dose-Response Relationship, Drug, Double-Blind Method, Female, Ganglionic Blockers, Humans, Male, Mecamylamine, Pilot Projects, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
